EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma,Clinical and Translational Medicine

当前位置： X-MOL 学术 › Clinical and Translational Medicine › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma
Clinical and Translational Medicine ( IF 7.919 ) Pub Date : 2022-02-20 , DOI: 10.1002/ctm2.722
Guangtong Deng _{1,

2} , Furong Zeng _{1,

2,

3} , Yi He _{1,

2} , Yu Meng _{1,

2} , Huiyan Sun _{1,

2} , Juan Su _{1,

2} , Shuang Zhao _{1,

2} , Yan Cheng ₄ , Xiang Chen _{1,

2} , Mingzhu Yin _{1,

2}

Affiliation

Despite the remarkable breakthroughs achieved in the management of metastatic melanoma using immunotherapy and targeted therapies, long-term clinical efficacy is often compromised due to dose-limiting toxicity and innate or acquired resistance. Therefore, it is of vital importance to further explore the molecular mechanisms underlying melanoma progression and identify new targeted therapeutic approaches.

中文翻译：

EEF2K 沉默通过抑制 SPP1 抑制肿瘤进展，并与黑色素瘤中的 BET 抑制剂协同作用

尽管使用免疫疗法和靶向疗法在转移性黑色素瘤的治疗方面取得了显着的突破，但由于剂量限制性毒性和先天性或获得性耐药性，长期临床疗效常常受到损害。因此，进一步探索黑色素瘤进展的分子机制并确定新的靶向治疗方法至关重要。

更新日期：2022-02-21

点击分享查看原文

点击收藏

公开下载